Acurx Announces FDA Has Granted an End of Phase 2 Meeting fo

As previously announced, planning is underway with FDA to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection As anticipated, an End of Phase 2...

Related Keywords

United States , America , Davidp Luci , , Prnewswire Acurx Pharmaceuticals Inc , Company Scientific Advisory Board , Acurx Pharmaceuticals , European Medicines Agency , Exchange Commission On Form , Society Or Healthcare Epidemiology Of America , Drug Administration , Data Monitoring Committee , Infectious Diseases Society Of America , Acurx Pharmaceuticals Inc , Nasdaq , Trial Oversight Committee , Company Ph , Briefing Document , Medium Sized Enterprise , New Drug Application , Meeting Request , Meeting Package , Scientific Advice , Marketing Authorizations , Executive Chairman , Marketing Authorization , Ibezapolstat Phase , Scientific Advisory Board , Clinical Cure , Modified Intent , Treat Population , Per Protocol Population , Prescribing Information , Independent Data Monitoring Committee , Fast Track Designated , Gram Positive Selective Spectrum , Qualified Infectious Disease Product , Generating New Antibiotic Incentives Now , Clinical Practice Guidelines , Infectious Diseases Society , Healthcare Epidemiology , New England Journal , Bile Acid , Private Securities Litigation Reform Act , Exchange Commission , Markets ,